Comparative Pharmacology
Head-to-head clinical analysis: THEOLAIR SR versus THEOPHYL SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOLAIR SR versus THEOPHYL SR.
THEOLAIR-SR vs THEOPHYL-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and antagonizing adenosine receptors.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/mL.
None Documented
None Documented
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Adults: 8-10 hours (range 3-12); Neonates: 20-30 hours; Smokers: 4-5 hours; Cirrhosis: 30-40 hours. Dose adjustments needed based on half-life variations.
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Renal: ~10% unchanged; Hepatic metabolism (90%) via CYP1A2, 3A4; metabolites (caffeine, 3-methylxanthine) excreted renally. Total clearance predominantly hepatic.
Category C
Category C
Bronchodilator
Bronchodilator